Grams Morgan E, Yang Wei, Rebholz Casey M, Wang Xue, Porter Anna C, Inker Lesley A, Horwitz Edward, Sondheimer James H, Hamm L Lee, He Jiang, Weir Matthew R, Jaar Bernard G, Shafi Tariq, Appel Lawrence J, Hsu Chi-Yuan
Division of Nephrology, Johns Hopkins University, Baltimore, MD; Welch Center for Prevention, Epidemiology & Clinical Research, Johns Hopkins University, Baltimore, MD; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Am J Kidney Dis. 2017 Sep;70(3):337-346. doi: 10.1053/j.ajkd.2017.01.050. Epub 2017 Mar 30.
People with advanced chronic kidney disease are at risk for the development of end-stage renal disease (ESRD), but also many other adverse outcomes, including cardiovascular disease (CVD) events and death. Determination of risk factors that explain the variability in prognosis and timing of these adverse outcomes can aid patient counseling and medical decision making.
Prospective research cohort.
SETTING & PARTICIPANTS: 1,798 participants with estimated glomerular filtration rates (eGFRs)<30mL/min/1.73m in the CRIC Study were followed up for a median of 5.5 years.
Age, race, sex, eGFR, proteinuria, diabetes mellitus, body mass index, ejection fraction, systolic blood pressure, history of CVD, and smoking history.
ESRD, CVD (congestive heart failure, stroke, myocardial infarction, and peripheral artery disease), and death.
Baseline age of the cohort was 60 years, 46% were women, and 46% were African American. Although 52.3% of participants progressed to ESRD during follow-up, the path by which this occurred was variable. For example, predicted 1-year probabilities for a hypothetical 60-year-old white woman with eGFR of 30mL/min/1.73m, urine protein excretion of 1.8g/d, and no diabetes or CVD (risk characteristics similar to the average participant) were 3.3%, 4.1%, and 0.3%, for first developing CVD, ESRD, and death, respectively. For a 40-year-old African American man with similar characteristics but higher systolic blood pressure, the corresponding 1-year probabilities were 2.4%, 13.2%, and 0.1%. For all participants, the development of ESRD or CVD increased the risk for subsequent mortality, with no differences by patient race or body mass index.
The CRIC population was specifically recruited for kidney disease, and the vast majority had seen a nephrologist.
The prognosis and timing of adverse outcomes in chronic kidney disease vary by patient characteristics. These results may help guide the development of personalized approaches for managing patients with advanced CKD.
晚期慢性肾脏病患者有发展为终末期肾病(ESRD)的风险,同时也面临许多其他不良后果,包括心血管疾病(CVD)事件和死亡。确定能够解释这些不良后果预后和发生时间变异性的危险因素,有助于为患者提供咨询服务并辅助医疗决策。
前瞻性研究队列。
慢性肾脏病队列研究(CRIC研究)中1798例估算肾小球滤过率(eGFR)<30mL/min/1.73m²的参与者,中位随访时间为5.5年。
年龄、种族、性别、eGFR、蛋白尿、糖尿病、体重指数、射血分数、收缩压、CVD病史和吸烟史。
ESRD、CVD(充血性心力衰竭、中风、心肌梗死和外周动脉疾病)和死亡。
队列的基线年龄为60岁,46%为女性,46%为非裔美国人。尽管52.3%的参与者在随访期间进展为ESRD,但其发生途径各不相同。例如,对于一名假设的60岁白人女性,eGFR为30mL/min/1.73m²,尿蛋白排泄量为1.8g/d,且无糖尿病或CVD(风险特征与平均参与者相似),首次发生CVD、ESRD和死亡的预测1年概率分别为3.3%、4.1%和0.3%。对于一名40岁的非裔美国男性,具有相似特征但收缩压较高,相应的1年概率分别为2.4%、13.2%和0.1%。对于所有参与者,ESRD或CVD的发生会增加随后死亡的风险,患者种族或体重指数之间无差异。
CRIC研究人群是专门针对肾脏疾病招募的,绝大多数人看过肾病科医生。
慢性肾脏病不良后果的预后和发生时间因患者特征而异。这些结果可能有助于指导制定针对晚期CKD患者的个性化管理方法。